Enhanced anjtitumorigenic effects in glioblastoma on double Targeting of pleiotrophin and its receptor ALK

Neoplasia

Volumn 11, Issue 2, 2009, Pages 145-156

  Grzelinski, Marius ^a   Steinberg, Florian ^a   Martens, Tobias ^b   Czubayko, Frank ^a   Lamszus, Katrin ^b   Aigner, Achim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MIDKINE; PLEIOTROPHIN; PROTEIN TYROSINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYTOKINE; MESSENGER RNA; PROTEIN TYROSINE KINASE; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; RIBOZYME;

ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; PROTEIN-TYROSINE KINASES; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, CATALYTIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61349164241     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81040     Document Type: Article

References (52)

1. Holland EC (2000). Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97 (12), 6242-6244.
2. Zhang N, Zhong R, Wang ZY, and Deuel TF (1997). Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J Biol Chem 272, 16733-16736.
3. Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A, Heidenreich A, Weinknecht S, Czubayko F, et al. (2003). Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14 (10), 1525-1529.
4. Jager R, Noll K, Havemann K, Pfluger KH, Knabbe C, Rauvala H, and Zugmaier G (1997). Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 73 (4), 537-543.
5. Czubayko F, Schulte AM, Berchem GJ, and Wellstein A (1996). Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 93, 14753-14758.
6. Mailleux P, Vanderwinden JM, and Vanderhaeghen JJ (1992). The new growth factor pleiotrophin (HB-GAM) mRNA is selectively present in the meningothelial cells of human meningiomas. Neurosci Lett 142, 31-35.
7. Fang WJ, Hartmann N, Chow D, Riegel AT, and Wellstein A (1992). Pleiotrophin stimulates fibroblasts, endothelial and epithelial cells, and is expressed in human cancer. J Biol Chem 267, 25889-25897.
8. Klomp HJ, Zernial O, Flachmann S, Wellstein A, and Juhl H (2002). Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients. Clin Cancer Res 8 (3), 823-827.
9. Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, and Wellstein A (1996). Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ line insertion of an endogenous retrovirus. Proc Natl Acad Sci USA 93, 14759-14764.
10. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, and Brodeur GM (1995). Differential expression of pleiotrophin and midkine in advanced neuroblastoma. Cancer Res 55, 1792-1797.
11. Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, von Schack D, Chin DJ, Lohr SC, Westphal M, et al. (2003). A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22 (43), 6661-6668.
12. Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Muller S, Fillbrandt R, Westphal M, and Lamszus K (2003). Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.J Neuropathol Exp Neurol 62 (12), 1265-1275.
13. Mentlein R and Held-Feindt J (2002). Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem 83 (4), 747-753.
14. Czubayko F, Riegel AT, and Wellstein A (1994). Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 269, 21358-21363.
15. Choudhuri R, Zhang HT, Donnini S, Ziche M, and Bicknell R (1997). An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57, 1814-1819.
16. Courty J, Dauchel MC, Caruelle D, Perderiset M, and Barritault D (1991). Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun 180, 145-151.
17. Rauvala H (1989). An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J 8, 2933-2941.
18. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, Milbrandt J, and Deuel TF (1990). Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 250, 1690-1694.
19. Weber D, Klomp HJ, Czubayko F, Wellstein A, and Juhl H (2000). Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 60 (18), 5284-5288.
20. Satyamoorthy K, Oka M, and Herlyn M (2000). An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res 13 (Suppl 8), 87-93.
21. Grzelinski M, Bader N, Czubayko F, and Aigner A (2005). Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer 117, 942-951.
22. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S, Czubayko F, and Aigner A (2006). RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17 (7), 751-766.
23. Bowden ET, Stoica GE, and Wellstein A (2002). Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 277 (39), 35862-35868.
24. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, et al. (2001). Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276 (20), 16772-16779.
25. Powers C, Aigner A, Stoica GE, McDonnell K, and Wellstein A (2002). Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 277 (16), 14153-14158.
26. Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME, and Vardiman JW (1989). The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 3 (12), 866-870.
27. Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, Magaud JP, Nezelof C, Tilly H, Vannier JP, et al. (1990). CD30-positive large cell lymphomas ("Ki-1 lymphoma") are associated with a chromosomal translocation involving 5q35. Br J Haematol 74 (2), 161-168.
28. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, and Look AT (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (5151), 1281-1284.
29. Pulford K, Morris SW, and Turturro F (2004). Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199 (3), 330-358.
30. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, and Deuel TF (2000). Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA 97 (6), 2603-2608.
31. Perez-Pinera P, Zhang W, Chang Y, Vega JA, and Deuel TF (2007). Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 282 (39), 28683-28690.
32. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, and Lamszus K (2006). RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem 98 (5), 1497-1506.
33. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, and Lamszus K (2001). Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61 (18), 6624-6628.
34. Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML, Czubayko F, and Aigner A (2004). Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 321 (2), 403-412.
35. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, and Kern FG (1990). Autocrine growth stimulation by secreted Kaposi's fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1, 63-71.
36. Liang CC, Park AY, and Guan JL (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2 (2), 329-333.
37. Muramatsu T (2002). Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 132 (3), 359-371.
38. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, and Wellstein A (2002). Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277 (39), 35990-35998.
39. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, and Mischel PS (2005). Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 280 (29), 26953-26964.
40. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Creminon C, and Vigny M (2005). Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 280 (28), 26039-26048.
41. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, and Lamszus K (2003). Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52 (6), 1391-1399; discussion 1399.
42. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, and Wang ZY (2002). Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys 397 (2), 162-171.
43. Degoutin J, Vigny M, and Gouzi JY (2007). ALK activation induces Shc and FRS2 recruitment: signaling and phenotypic outcomes in PC12 cells differentiation. FEBS Lett 581 (4), 727-734.
44. Souttou B, Carvalho NB, Raulais D, and Vigny M (2001). Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 276 (12), 9526-9531.
45. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, and Courty J (2004). Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGFinduced angiogenesis. Oncogene 23 (9), 1745-1753.
46. Samuels Y and Ericson K (2006). Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 (1), 77-82.
47. Cohen P and Frame S (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2 (10), 769-776.
48. Jope RS, Yuskaitis CJ, and Beurel E (2007). Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32 (4-5), 577-595.
49. Zhu J, Blenis J, and Yuan J (2008). Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci USA 105 (18), 6584-6589.
50. Sarto C, Binz PA, and Mocarelli P (2000). Heat shock proteins in human cancer. Electrophoresis 21 (6), 1218-1226.
51. Zhang R, Tremblay TL, McDermid A, Thibault P, and Stanimirovic D (2003). Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 42 (2), 194-208.
52. Aigner A (2007). Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76 (1), 9-21.